Rigel Pharmaceuticals (Rigel Pharmaceuticals) Growth Rank : 10 (As of Apr. 25, 2024)

View and export this data going back to 2000. Start your Free Trial

What is Rigel Pharmaceuticals Growth Rank?

Rigel Pharmaceuticals has the Growth Rank of 10.

GuruFocus Growth Rank measures the growth of a company in terms of its revenue and profitability. Historically, the companies with the highest growth ranks performed the best over the long term. It is calculated using the following criteria:

1. 5-year revenue growth rate, the higher, the better.
2. 3-year revenue growth rate, the higher, the better.
3. 5-year EBITDA growth rate, the higher, the better.
4. The predictability of 5-year revenue. The most consistent it is, the higher the rank.

GuruFocus found that the Growth Rank is the second of the two most-sensitive parameters among the five parameters checked. Please click GF Score to see more details on GF Score's 5 Key Aspects of Analysis.

Please note that we are using the five-year EBITDA growth rate as a parameter, so the company needs to have had positive growth over that time. The reason we use EBITDA instead of earnings per share is that with EBITDA, we can rank a lot more companies since a company may have positive EBITDA but negative EPS. Since we are looking at the growth here, EBITDA gives us a pretty clear picture about the growth in the company's business operations.

Competitive Comparison of Rigel Pharmaceuticals's Growth Rank

For the Biotechnology subindustry, Rigel Pharmaceuticals's Growth Rank, along with its competitors' market caps and Growth Rank data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Rigel Pharmaceuticals's Growth Rank Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Rigel Pharmaceuticals's Growth Rank distribution charts can be found below:

* The bar in red indicates where Rigel Pharmaceuticals's Growth Rank falls into.

Rigel Pharmaceuticals Growth Rank Related Terms

Thank you for viewing the detailed overview of Rigel Pharmaceuticals's Growth Rank provided by GuruFocus.com. Please click on the following links to see related term pages.

Rigel Pharmaceuticals (Rigel Pharmaceuticals) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Rigel Pharmaceuticals Inc (NAS:RIGL) » Definitions » Growth Rank

Comparable Companies

Traded in Other Exchanges

RI2A:Germany

Address

611 Gateway Boulevard, Suite 900, South San Francisco, CA, USA, 94080

Website

https://www.rigel.com

Rigel Pharmaceuticals Inc develops small-molecule drugs for autoimmune, cancer-related, and viral diseases. The firm's lead drug is an oral rheumatoid arthritis drug candidate that has been licensed to AstraZeneca. Astra has taken overall responsibility to develop and market the drug and will pay Rigel royalties and milestone payments. Its pipeline product includes TAVALISSE (fostamatinib disodium hexahydrate) tablets, the only oral spleen tyrosine kinase (SYK) inhibitor, Fostamatinib, R289, R552, R835, DS-3032, THF-beta Inhibitors, and AZD0449- Inhaled JAK Inhibitor.

Executives

Raul R Rodriguez	officer: Sr VP of Bus Dev and Com Ops	1180 VETERANS BOULEVARD, SOUTH SAN FRANCISCO CA 94080
David A Santos	officer: EVP, Chief Commercial Officer	RIGEL PHARMACEUTICALS, INC., 1180 VETERANS BLVD., SOUTH SAN FRANCISCO CA 94080
Wolfgang Dummer	officer: EVP & CMO	5491 OPTICAL CT., SAN JOSE CA 95138
Dean L Schorno	officer: EVP & Chief Financial Officer	301 PENOBSCOT DRIVE, REDWOOD CITY CA 94063
Raymond J. Furey	officer: EVP, GC & Corp Sec	1300 N. KELLOGG DRIVE, SUITE D, ANAHEIM CA 92807
Alison L. Hannah	director	12701 COMMONWEALTH DRIVE, SUITE 9, FORT MYERS FL 33913
Gary A Lyons	director	12790 EL CAMINO REAL, C/O NEUROCRINE BIOSCIENCES, SAN DIEGO CA 92130
Anthony Gregg Lapointe	director	PO BOX 83216, GAITHERSBURG MD 20883-3216
Brian L. Kotzin	director	RIGEL PHARMACEUTICALS, INC., 1180 VETERANS BOULEVARD, SOUTH SAN FRANCISCO CA 94060
Kamil Ali-jackson	director	C/O ACLARIS THERAPEUTICS, INC., 101 LINDENWOOD DRIVE, SUITE 400, MALVERN PA 19355
Jane Wasman	director	C/O ACORDA THERAPEUTICS, INC., 420 SAW MILL RIVER ROAD, ARDSLEY NY 10502
Nelson Cabatuan	officer: Principal Accounting Officer	RIGEL PHARMACEUTICALS, INC., 1180 VETERANS BLVD., SOUTH SAN FRANCISCO CA 94080
Anne-marie Duliege	officer: Chief Medical Officer	4001 MIRANDA AVENUE, PALO ALTO CA 94304
Mayer Eldon C. Iii	officer: EVP & Chief Commercial Officer	RIGEL PHARMACEUTICALS, INC., 1180 VETERANS BLVD., SOUTH SAN FRANCISCO CA 94080
Stacy Markel	officer: EVP Human Resources	RIGEL PHARMACEUTICALS, INC., 1180 VETERANS BLVD., SUITE 400, SOUTH SAN FRANCISCO CA 94080